Europe's first dual orexin receptor antagonist – QUVIVIQ (daridorexant) – granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder Marketscreener.com
Europe's first dual orexin receptor antagonist – QUVIVIQ (daridorexant) – granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder GlobeNewswire
What Are The Benefits, And Drawbacks, Of Mental Health Apps? CBS Minnesota
Global Mental Health: Due to the fifth wave of Covid-19, a record-breaking 75% of Hong Kong people are suffering from depression, with stress levels far exceeding Japan, Taiwan, and Malaysia. Digital Journal
Global Mental Health: Due to the fifth wave of Covid-19, a record-breaking 75% of Hong Kong people are su Benzinga
LGBTQ+ community marks 50th anniversary of historic "Dr. Anonymous" speech Victoria Advocate
Your Monday Evening Briefing The New York Times
In Heard–Depp defamation trial, the stigma of BPD looms large Salon
Sports betting is exploding. This ex-gambler has a $15,000 cautionary tale Detroit News
